Phase III Clinical Trial COMPETE with n.c.a. 177Lu-Edotreotide (Solucin®) in Cancer Patients with GEP-NET compared to mTOR inhibitor Everolimus.
Do you want to learn about ITM’s #PrecisionOncology approach? Are you interested in why we enjoy our work?
Or do you simply want to know who we are and what #TargetedRadionuclideTherapy is?
Enjoy finding your answers in this video!
Find challenging opportunities within the ITM Group. Our employees are a key success factor, as each individual contributes to the overall success of the Company through his/her work ...